Biomarker for Morquio Disease (BioMorquio)

Sponsor

CENTOGENE GmbH Rostock (Industry)

Overall Status

Active, not recruiting

CT.gov ID

NCT01457456

Collaborator

(none)

1,000

Enrollment

Locations

35.4

Anticipated Duration (Months)

200

Patients Per Site

5.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Development of a new MS-based biomarker for the early and sensitive diagnosis of Morquio disease from plasma

Condition or Disease	Intervention/Treatment	Phase
Morquio Syndrome Accumulation of Mucopolysaccharides Morquio Syndrome A Morquio B Disease

Detailed Description

Morquio syndrome (mucopolysaccharidosis type IV; MPS IV) is a mucopolysaccharide storage disease that exists in two forms (Morquio syndromes A and B) and occurs because of a deficiency of the enzymes N-acetyl-galactosamine-6-sulfatase and beta-galactosidase, respectively. A deficiency of either enzyme leads to the accumulation of mucopolysaccharides in the body, abnormal skeletal development, and additional symptoms. In most cases, individuals with Morquio syndrome have normal intelligence. The clinical features of MPS IV-B are less severe than those associated with MPS IV-A. Symptoms may include growth retardation, a prominent lower face, an abnormally short neck, knees that are abnormally close together (knock knees or genu valgum), flat feet, abnormal sideways and front-to-back or side-to-side curvature of the spine (kyphoscoliosis), abnormal development of the growing ends of the long bones (epiphyses) resulting in dwarfism, and/or a prominent breast bone (pectus carinatum) as well as bell shaped chest. Though the CNS and peripheral nerves are primarily not affected the bone defects may result in neurological symptoms such as spinal cord compression. Hearing loss, weakness of the legs, and/or additional abnormalities may also occur.

The mucopolysaccharidoses (MPS) are a group of inherited lysosomal storage disorders. Lysosomes function as the primary digestive units within cells. Enzymes within lysosomes break down or digest particular nutrients, such as certain carbohydrates and fats. In individuals with MPS disorders, deficiency or malfunction of specific lysosomal enzymes lead to an abnormal accumulation of certain complex carbohydrates (mucopolysaccharides or glycosaminoglycans) in the arteries, skeleton, eyes, joints, ears, skin and/or teeth. These accumulations may also be found in the respiratory system, liver, spleen, central nervous system, blood, and bone marrow. This accumulation eventually causes progressive damage to cells, tissues, and various organ systems of the body. There are several different types and subtypes of mucopolysaccharidosis. These disorders, with one exception, are inherited as autosomal recessive traits and all vary in their clinical phenotype. Within our clinical trial we focus on MPS type IV.

New methods, like mass-spectrometry give a good chance to characterize in the blood (plasma) of affected patents specific metabolic alterations that allow to diagnose in the future the disease earlier, with a higher sensitivity and specificity. Therefore it is the goal of the study to develop new biochemical markers from the plasma of the affected patients helping to benefit the patient by an early diagnose and thereby with an earlier treatment.

Study Design

Study Type:

Observational

Anticipated Enrollment :

1000 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Biomarker for Morquio Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL

Actual Study Start Date :

Aug 20, 2018

Anticipated Primary Completion Date :

Aug 1, 2021

Anticipated Study Completion Date :

Aug 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Observation Patients with Morquio disease

Outcome Measures

Primary Outcome Measures

Development of a new MS-based biomarker for the early and sensitive diagnosis of Morquio disease from blood (plasma) [24 month]
New methods, like mass-spectrometry give a good chance to characterize specific metabolic alterations in the blood of affected patients that allow diagnosing in the future the disease earlier, with a higher sensitivity and specificity.

Secondary Outcome Measures

Testing for clinical robustness, specificity and long-term stability of the biomarker [36 months]
the goal of the study to identify and validate a new biochemical marker from the blood of the affected patients helping to benefit other patients by an early diagnose and thereby with an earlier treatment

Eligibility Criteria

Criteria

Ages Eligible for Study:

12 Months and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

INCLUSION CRITERIA:

Informed consent will be obtained from the patient or the parents before any study related procedures
Patients older than 12 months
The patient has a diagnosis of Morquio disease

EXCLUSION CRITERIA:

No Informed consent from the patient or the parents before any study related procedures.
Patients younger than 12 months
The patient has no diagnosis of Morquio disease

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Children's Hospital, Faculty of Medicine, Ain Shams University	Cairo		Egypt	89075
2	Centogene AG	Rostock		Germany	18055
3	Amrita Institute of Medical Sciences & Research Centre	Cochin	Kerala	India	682041
4	Navi Mumbai Institute of Research In Mental And Neurological Handicap (NIRMAN)	Mumbai		India	400705
5	Lady Ridgeway Hospital for Children	Colombo 8		Sri Lanka	00800c